Sigma-Aldrich Amenamevir

Amenamevir (ASP2151) is an orally active and potent helicase-primase complex inhibitor with equipotency against viral DNA replication of varicella-zoster virus (VZV Ellen EC50/EC90 = 47/460 nM) and herpes simplexvirus (EC50/EC90 = 36/230 nM using HSV-1 (KOS) & 28/460 nM using HSV-2(g)). This antiherpetic agent prevents the replication of these viruses. Amenamevir is much more potent (EC50 38-100 nM) than acyclovir (EC50 = 1.3-2.7 µM) against all VZV strains tested and is active against aciclovir-resistant VZV. This oxadiazolephenyl derivative is 14-times more potent than valaciclovir in azosteriform-spread model among mice infected with HSV-1 in vivo (EC50 =1.9 vs. 27 mg/kg, respectively, via twice daily p.o.).

Amenamevir may beused in laboratory studies to investigate the mechanisms of viral replication,particularly in the context of herpes simplex virus (HSV) and varicella-zostervirus (VZV) infections. It may also be used as a model compound in thedevelopment of other antiviral agents, helping researchers understand thestructure-activity relationship of helicase-primase inhibitors.

Orally active and potent helicase-primase complex inhibitor with equipotency against varicella-zoster virus (VZV) and herpes simplex virus (HSV-1 & HSV-2).